Raymond James & Associates’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $217K | Sell |
14,119
-333
| -2% | -$5.12K | ﹤0.01% | 3567 |
|
|
2024
Q2 | $235K | Buy |
14,452
+1,643
| +13% | +$26.7K | ﹤0.01% | 3486 |
|
|
2024
Q1 | $237K | Buy |
+12,809
| New | +$237K | ﹤0.01% | 3495 |
|
|
2023
Q4 | – | Sell |
-10,614
| Closed | -$221K | – | 3771 |
|
|
2023
Q3 | $221K | Buy |
10,614
+1,630
| +18% | +$34K | ﹤0.01% | 3376 |
|
|
2023
Q2 | $215K | Buy |
+8,984
| New | +$215K | ﹤0.01% | 3410 |
|
|
2021
Q1 | – | Sell |
-31,372
| Closed | -$1.68M | – | 3822 |
|
|
2020
Q4 | $1.68M | Buy |
+31,372
| New | +$1.68M | ﹤0.01% | 1997 |
|
|
2020
Q3 | – | Sell |
-17,073
| Closed | -$828K | – | 3460 |
|
|
2020
Q2 | $828K | Sell |
17,073
-2,307
| -12% | -$112K | ﹤0.01% | 2274 |
|
|
2020
Q1 | $819K | Sell |
19,380
-2,390
| -11% | -$101K | ﹤0.01% | 2108 |
|
|
2019
Q4 | $931K | Buy |
21,770
+7,672
| +54% | +$328K | ﹤0.01% | 2303 |
|
|
2019
Q3 | $507K | Sell |
14,098
-633
| -4% | -$22.8K | ﹤0.01% | 2631 |
|
|
2019
Q2 | $394K | Buy |
+14,731
| New | +$394K | ﹤0.01% | 2817 |
|
|
2017
Q1 | – | Sell |
-16,289
| Closed | -$470K | – | 3132 |
|
|
2016
Q4 | $470K | Buy |
16,289
+1,896
| +13% | +$54.7K | ﹤0.01% | 2363 |
|
|
2016
Q3 | $458K | Buy |
14,393
+5,749
| +67% | +$183K | ﹤0.01% | 2336 |
|
|
2016
Q2 | $281K | Buy |
8,644
+440
| +5% | +$14.3K | ﹤0.01% | 2439 |
|
|
2016
Q1 | $229K | Sell |
8,204
-51,347
| -86% | -$1.43M | ﹤0.01% | 2493 |
|
|
2015
Q4 | $2.12M | Buy |
59,551
+2,744
| +5% | +$97.8K | 0.01% | 1232 |
|
|
2015
Q3 | $1.88M | Buy |
56,807
+6,636
| +13% | +$219K | 0.01% | 1250 |
|
|
2015
Q2 | $2.1M | Buy |
50,171
+2,295
| +5% | +$96.1K | 0.01% | 1288 |
|
|
2015
Q1 | $1.56M | Sell |
47,876
-4,225
| -8% | -$138K | 0.01% | 1392 |
|
|
2014
Q4 | $1.65M | Buy |
+52,101
| New | +$1.65M | 0.01% | 1272 |
|